scispace - formally typeset
S

Shiro Kobayashi

Researcher at University of California, Berkeley

Publications -  89
Citations -  6269

Shiro Kobayashi is an academic researcher from University of California, Berkeley. The author has contributed to research in topics: Finite element method & Stress (mechanics). The author has an hindex of 31, co-authored 87 publications receiving 6143 citations.

Papers
More filters
Journal ArticleDOI

Process sequence design in cold extrusion to form an axisymmetric shell body

TL;DR: In this article, the multi-stage cold extrusion process to produce a steel axisymmetric shell body is investigated for process sequence design by using the finite element method, where the main design goal is to obtain the optimum process sequence which can produce the required part most economically.
Journal ArticleDOI

Influence of hospital capabilities and prehospital time on outcomes of thrombectomy for stroke in Japan from 2013 to 2016

Ai Kurogi, +572 more
- 28 Feb 2022 - 
TL;DR: In this article , the influence of mechanical thrombectomy (MT) use, the CSC score, and the total EMS response time on the modified Rankin Scale score at discharge among patients with acute ischemic stroke transported by ambulance, in phases I (2013-2014, 1461 patients) and II (2015-2016, 3259 patients).
Journal ArticleDOI

Superplastic forging design of a jet engine disk by the finite element method

TL;DR: In this paper, the authors derive systematic procedures in superalloy engine disk forging, and develop a scheme to control strain-rate within the range of superplastic deformation during the forging operation.
Journal ArticleDOI

Influence of hospital capabilities and prehospital time on outcomes of thrombectomy for stroke in Japan from 2013 to 2016

Ai Kurogi, +572 more
- 28 Feb 2022 - 
TL;DR: In this article , the influence of mechanical thrombectomy (MT) use, the CSC score, and the total EMS response time on the modified Rankin Scale score at discharge among patients with acute ischemic stroke transported by ambulance, in phases I (2013-2014, 1461 patients) and II (2015-2016, 3259 patients).